Skip to main content
Clinical Trials/NCT05877027
NCT05877027
Completed
Not Applicable

Comparison of Commonly Used Treatment Approaches in the Treatment of Gonarthrosis: Platelet-Rich Plasma, Topical Diclofenac, and Exercise

Istanbul University - Cerrahpasa1 site in 1 country82 target enrollmentMarch 20, 2024
ConditionsGonarthrosis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Gonarthrosis
Sponsor
Istanbul University - Cerrahpasa
Enrollment
82
Locations
1
Primary Endpoint
Change of Pain via Numeric Pain Rating Scale
Status
Completed
Last Updated
8 months ago

Overview

Brief Summary

Osteoarthritis, the most common type of arthritis, is a chronic and degenerative joint disease. It has been reported to affect more than 300 million adults and elderly individuals worldwide. The joint most commonly affected by osteoarthritis is the knee joint and this condition is called gonarthrosis.

The goal of treatment is to reduce symptoms and ultimately slow the progression of the disease with various treatment options throughout the course of the disease.Current clinical studies prepared by the working groups of the International Osteoarthritis Research Society (OARSI) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) According to the guidelines, treatment typically includes physiotherapy interventions with the use of non-steroidal anti-inflammatory drugs (NSAIDs) and analgesics, including intra-articular injections of corticosteroids. Exercise-oriented physiotherapy is one of the main approaches for the conservative treatment of gonarthrosis. The curative clinical effect of exercise therapy on pain and functional disability in gonarthrosis is important.

The use of PRP in the treatment of gonarthrosis is based on the ability of platelets to release biologically active proteins and promote tissue healing. Since the cartilage tissue mainly affected in gonarthrosis has low healing potential, this feature of platelets becomes more important for the target tissue. Existing studies show that PRP is superior to hyaluronic acid in intermediate and initial gonarthrosis; on the other hand, less satisfactory results are reported in severe gonarthrosis, similar to viscosupplementation.

Topically or orally administered NSAIDs form the backbone of pharmacological treatment in gonarthrosis.

It is seen that both exercise, PRP and topical NSAID agents are among the recommendations in the treatment of gonarthrosis. However, there is insufficient evidence regarding the superiority and therapeutic efficacy of these three treatment approaches. The aim of this study is to determine the effectiveness of "exercise", "PRP" and "NSAID-specific topical agents" in the treatment of patients with gonarthrosis; pain, function, quality of life, and patient satisfaction.

Detailed Description

Voluntary participants who have been diagnosed with gonarthritis will be included in the study. Signed voluntary consent will be obtained from participants. Participants will be divided into tree groups. Study groups will be as follows: a) exercise, b) topical diclofenac, c) platalet-rich-plasma (PRP).

Registry
clinicaltrials.gov
Start Date
March 20, 2024
End Date
May 18, 2025
Last Updated
8 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Istanbul University - Cerrahpasa
Responsible Party
Principal Investigator
Principal Investigator

Sezen Karaborklu Argut

Principal Investigator

Istanbul University - Cerrahpasa

Eligibility Criteria

Inclusion Criteria

  • Diagnosed with gonarthrosis according to the criteria of the American Society of Rheumatology (ACR)
  • Stage 2 or 3 according to Kellgren Lawrence radiological staging criteria,
  • Those between the ages of 40 and 65,
  • Body mass index below 30 kg/m2,
  • Pain intensity defined by the patient in the last 3 months is at least 3 out of 10 according to NPRS,
  • Patients who do not have any barriers to being included in the exercise program

Exclusion Criteria

  • Being in stage 4 according to Kellgren Lawrence radiological staging criteria,
  • Hemoglobin level \<11.5 g/dL
  • Platelet level \<100,000/μL
  • Thrombocytopenia, coagulopathy, crystal arthropathy, hemophilia or hematological malignancy,
  • Presence of active infection or tumor,
  • Chronic antiaggregant use or taking immunosuppressive therapy,
  • Pregnancy or lactation,
  • Viscosupplementation or steroid injection in the related knee in the last 3 months, or using systemic steroids,
  • To have received a physiotherapy program for the relevant knee in the last 3 months,
  • Having a valgus or varus deformity greater than 15°,

Outcomes

Primary Outcomes

Change of Pain via Numeric Pain Rating Scale

Time Frame: change from baseline pain at 6 months

On this scale, "0" indicates the absence of pain, and "10" indicates the most severe pain imaginable. Patients will be asked to rate the severity of their knee pain with a number between 0 and 10 using this scale. The minimum clinically significant difference value (MCID) of this valid and reliable pain scale is 1.74 points.

Secondary Outcomes

  • 40 meters fast walking test(4 times for 24 weeks)
  • Stepping Test(4 times for 24 weeks)
  • WOMAC(4 times for 24 weeks)
  • Global Rating of Change Scale-GRC(4 times for 24 weeks)
  • Joint Range of Motion Evaluation(4 times for 24 weeks)
  • Health-Related Quality of Life Short Form-12 Scale (SF-12)(4 times for 24 weeks)

Study Sites (1)

Loading locations...

Similar Trials